Introduction:
This article discusses the potential of natural killer (NK) cells in cell therapy for cancer and autoimmune diseases. Scientists at Artiva Biotherapeutics in San Diego are working on developing allogeneic NK cell therapies that do not require genetic modification. NK cells can be targeted using antibodies to attack and kill cancer cells or immune system B cells. The use of allogeneic NK cells avoids the risk of graft-versus-host disease and serious cytokine release syndrome associated with T-cell therapies. Artiva’s manufacturing process, developed by GC Cell in South Korea, allows for the production of large quantities of cryo-preserved NK cells for off-the-shelf treatments.
- Artiva Biotherapeutics is developing allogeneic NK cell therapies for cancer and autoimmune diseases.
- NK cells can be targeted using antibodies to attack and kill cancer cells or immune system B cells.
- NK cells have advantages over T cells in terms of avoiding graft-versus-host disease and serious cytokine release syndrome.
- Artiva’s manufacturing process allows for large-scale production of cryo-preserved NK cells for off-the-shelf treatments.
Conclusion:
The use of allogeneic NK cells in cell therapy offers a promising approach for the treatment of cancer and autoimmune diseases. Artiva Biotherapeutics’ manufacturing process allows for easier access to NK-based cell therapies, addressing the challenges of time and cost in manufacturing. Further research and development in this area could lead to more effective and accessible treatments for patients.
